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Residing at the intersection of two relatively young
fields—psychopharmacology and pharmacogenetics—
psychopharmacogenetics is only now becoming rec-
ognized as a biomedical discipline in its own right.
The introduction of chlorpromazine, in 1952, for the
treatment of psychotic disorders, may be considered
to mark the birth of psychopharmacology. Since that
time, a wide array of psychotropic drugs have been
applied to the treatment of various psychiatric con-
ditions, including anxiety disorders and such mood
disorders as depression and mania.
Clinical experience quickly accumulated, indicating
that these drugs are of variable usefulness. Stark inter-
individual differences in outcome and side effects are
distressingly common for this group of therapeutic
drugs. Early on, and continuing to this day, psychiatrists
have relied on clinical experience and, not infrequently,
guesswork to predict the outcome of prescribing a stan-
dard dosage of a psychotropic drug. Increasingly, how-
ever, evidence—which is often anecdotal but which is
sometimes based on the results of family and twin stud-
ies—has suggested that genetic factors underlie (1) the
observed interindividual and interethnic or racial differ-
ences in psychopharmacological response (Smith and
Mendoza 1996; Frackiewicz et al. 1997; Varner et al.
1998) and (2) the concordant responses, among rela-
tives, to antidepressant therapy (Franchini et al. 1998).
Thus, perhaps to their own surprise, psychiatrists have
found themselves concerned about familial patterns of
drug kinetics and about polymorphisms in genes for re-
ceptors or enzymes, although both of these issues have
traditionally been the province of pharmacogeneticists.
As originally defined by Vogel (1959), pharmacoge-
netics is the study of the heritable differences in the me-
tabolism and activity of exogenous agents such as drugs
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or environmental toxins. In recent years, researchers in
pharmacogenetics have focused on evaluating structural
and regulatory polymorphisms both in genes coding for
drug-metabolizing enzymes and in genes coding for
other enzymes or receptors. Here, I wish to argue that
psychiatry should not overuse psychopharmacogenet-
ics as a tool to solve its own uncertainties, nor should
psychopharmacogenetics be viewed as a special facet
of pharmacogenetics. Instead, psychopharmacogenetics
should be seen as a separate field of inquiry with a spe-
cific set of challenges. Mental disorders are intrinsically
heterogeneous and can seldom be defined or diagnosed
by the same rigorous methods applied to other condi-
tions of interest to medical geneticists. In addition, the
interactions between genetic and environmental factors
that make psychiatric phenotypes difficult to study may
render equally difficult the pursuit of optimal individual
treatments for these diseases. Nevertheless, there is rea-
son for optimism, since, in this era of molecular biology,
psychopharmacogenetics now has appropriate tools at
its disposal for addressing these challenges.
Before the advent of molecular tools, researchers in
psychopharmacogenetics were restricted to examination
of questions about the kinetics and dynamics of psy-
choactive drugs. Animal models, which were a staple of
such work, have proved to be poor predictors of the
range of drug responses in humans. The ability to work
at the DNA level now allows researchers to identify and
score polymorphisms with ease. It also allows them to
tap into the insights of molecular neuroscientists, who
are concerned with the physiological and developmental
roles of genes that have come to our attention because
of their possible pathological roles.
Pharmacogenetics has often been used to solve the
problem of the biological heterogeneity of psychiatric
diseases. However, both the use of markers, such as hu-
man leukocyte antigens, that have a questionable rele-
vance to the disease process and the lack of reliable
diagnoses have led to inconclusive and contradictory
findings about the nosology of schizophrenia and affec-
tive (mood) disorders. Differences in response to treat-
ment do indeed provide potentially important clues to
these problems, primarily because they suggest different
etiopathogenetic hypotheses, but they absolutely cannot
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take the place of the reliable diagnostic criteria that we
are still obliged to seek. In its molecular form, however,
psychopharmacogenetics could help refine diagnoses
and provide a tool for independent genetic testing of a
given drug-responsive phenotype.
Drug-Metabolizing Enzymes and Receptor
Pharmacology
The earliest applications of molecular data in psychi-
atric treatment did little to address the familiar meth-
odological difficulties that arise from working with
poorly defined clinical entities. Unfortunately, psychi-
atric nosology has not seemed to have kept up with
progress in neurobiology and molecular biology (van
Praag 1997; Smoller and Tsuang 1998), and the etiologic
factors of major psychiatric disorders are still unknown,
despite considerable efforts and methodological ad-
vances (Peroutka 1997). This may reflect, in part, an
overly simplistic focus on individual receptor molecules,
despite the fact that most psychotropic drugs target mul-
tiple signaling pathways.
Although much of the variability in psychotropic
drug action is linked to genetic factors, the results of
studies of drug-metabolizing enzymes (DMEs) and re-
ceptor variants have proved, on the whole, to be con-
fusing and inconsistent. Thus, polymorphisms within
the CYP2D6 gene, which encodes a cytochrome P450
DME, have been extensively screened in psychiatric
patients, although there have been no conclusive re-
sults (Andreassen et al. 1997; Armstrong et al. 1997;
Kawanishi et al. 1997; Mihara et al. 1997a, 1997b;
de Leon et al. 1998; Kapitany et al. 1998). No clear-
cut explanation for interindividual differences in drug
plasma levels has emerged from this research. Drug
efficacy and side-effect patterns cannot be predicted
by genotyping at this locus, although there are some
consistent data regarding the variable risk of extra-
pyramidal side effects, including such movement dis-
orders as tardive dyskinesia (Armstrong et al. 1997;
Kapitany et al. 1998).
The dopamine D4 receptor (DRD4) gene, which ex-
hibits considerable genetic variability both within and
between populations, was initially studied as a candidate
risk factor for major psychiatric disorders; however, no
convincing associations have emerged. The pharmacol-
ogy of this receptor suggests that it might still be related
to variability in clinical response. DRD4 binds to the
antipsychotic drug clozapine, and several study groups
(Rietschel et al. 1996; Hwu et al. 1998) have obtained
conflicting results on how sequence variants effect re-
sponsiveness to this drug. An in vitro study on an ex-
pressed variant of DRD4 failed to show significant var-
iation either in the receptor’s affinity for clozapine or
for other drugs or neurotransmitters or in its functional
properties (Zenner et al. 1998). However, clozapine also
interacts with the serotonin receptors 5HT2C and
5HT2A (Meltzer 1994; Kuoppamaki et al. 1995), which
raises the question of whether variation at the corre-
sponding loci affects the efficacy of this drug. Indeed,
although some of the study groups (Sodhi et al. 1995;
Malhotra et al. 1996; Chen et al. 1997; Rietschel et al.
1997; Arranz et al. 1998a; Masellis et al. 1998) that
have examined this question have reported equivocal
results, Arranz et al. (1998b) have shown, by meta-anal-
ysis, that 5HT2A variants do appear to influence the
response to clozapine.
Psychopharmacogenetics clearly has not succeeded
in its pursuit of the DME polymorphisms that are at
the heart of much of pharmacogenetics, nor has it
succeeded in borrowing candidate genes from psy-
chiatric genetic studies. It remains possible that these
approaches will prove useful in the tailoring of in-
dividualized therapies. However, if the goal is to iden-
tify effective drug therapies for individuals with spe-
cific genetic backgrounds, then it seems that research
should be guided, as far as possible, by a molecular
description of the relevant disease processes and by
the presence of functional polymorphisms in candi-
date genes. I would like to suggest that our experience
with two psychiatric conditions—delusional depres-
sion and panic disorder—points the way toward a
more sophisticated use of genetic data in psychiatric
therapy.
Depression and the 5-HTT Promoter
Depression with psychotic features is a particularly
severe form of mood disorder, associated with high
recurrence rates, great long-term morbidity, and a low
response rate to either placebos or tricyclic antide-
pressants. Therefore, delusional depression seems to
represent a syndrome that is biologically more ho-
mogeneous than other mood disorders. Evidence from
studies in biochemistry, neuroendocrinology, and
pharmacology suggests that dysfunctions in seroto-
nergic pathways could play a pivotal, albeit nonex-
clusive, role in mood disorders. Patients with delu-
sional depression are commonly treated with the
selective serotonin-reuptake inhibitor (SSRI) fluvox-
amine, but SSRI nonresponders are not uncommon.
The addition of pindolol (a mixed b-adrenergic re-
ceptor [bAR] and 5-HT1A antagonist) has been pro-
posed as augmentation therapy for SSRI nonrespon-
ders or partial responders, but reliable predictive
criteria are needed. The serotonin transporter 5-HTT
plays a critical role in the termination of 5-HT neu-
rotransmission and represents the prime target for
SSRIs, a finding that suggests the 5-HTT gene as a
candidate for pharmacogenetic studies.
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Heils et al. (1996) first identified an allele of 5-HTT
with a 44-bp insertion in the promoter region. Studies
of transfected cells in culture show that the long and
short variants exhibit different transcriptional properties
(Lesch et al. 1996). The basal transcriptional activity of
the long variant is more than twice that of the short
variant, and choriocarcinoma cells containing the short
variant produce concentrations of 5-HTT mRNA that
are 30%–40% lower than those produced by the long
variant. Significantly, these differences in 5-HTTmRNA
synthesis result in different 5-HTT expression and 5-HT
cellular uptake (Lesch et al. 1996), which raises the pos-
sibility that individual differences in antidepressant re-
sponse, in the face of comparable SSRI bioavailability,
could result from differential expression of 5-HTT.
The presence of a functional polymorphism within the
promoter region of 5-HTT made the gene a good can-
didate and prompted my team and me to test whether
this sequence variability affects response to the use of
fluvoxamine, either alone or supplemented with pin-
dolol, in cases of delusional depression. In a recent study
(Smeraldi et al. 1998), we reported that, in patients with
delusional depression, the promoter polymorphism cor-
relates with the clinical response to fluvoxamine. To
avoid extreme differences in the bioavailability of the
drug, we excluded from the study those patients whose
steady-state fluvoxamine plasma levels were 11.96 SD
outside the mean value of the sample. Individuals who
were homozygous for the long variant of the 5-HTT
promoter showed a better response to treatment with
fluvoxamine alone than did those who were either het-
erozygous or homozygous for the short variant. Hence,
the antidepressant efficacy of fluvoxamine seems to be
related to allelic variation within this regulatory se-
quence. Moreover, this correlation appears to apply
more broadly to other depressive conditions for which
SSRIs are used. We obtained similar results when we
used the SSRI paroxetine in a sample of individuals with
nondelusional depression (Zanardi et al., in press).
Genotyping of the 5-HTT promoter appears to rep-
resent a promising approach to individualization of the
treatment of depression, since it identifies a subset of
patients—those who are homozygous for the short var-
iant in the promoter—who may require pindolol aug-
mentation therapy. Given the well-known and frustrat-
ing latency of antidepressant response, the ability to
identify such patients in advance could represent a sig-
nificant advance in the care of depression. Because pin-
dolol causes substantial side effects, primarily as a result
of its antagonism to bAR, genotyping of the 5-
HTT–linked polymorphic region could spare a large
number of patients the risk of harm from unnecessary
drug treatment. However, our results should be regarded
cautiously, since data on independent replication in other
samples and in other ethnic groups are still lacking.
Panic Disorder and the MAOA Promoter
The monoamine oxidase A (MAOA; see Shih and
Thompson 1999 [in this issue]) gene provides another
example of the use of genetics to tailor psychotropic-
drug administration to individual cases. BecauseMAOA
inhibitors are effective in the treatment of panic disorder,
the X-linkedMAOA gene might be expected to underlie
the disease or to affect the efficacy of these drugs in its
treatment. Therefore, we investigated a novel repeat
polymorphism in the MAOA promoter, to determine its
association with panic disorder. This polymorphism con-
sists of a 30-bp motif that repeats two to five times. One
variant, termed “3a,” carries three full repeats and one
partial repeat of this sequence. We found that these poly-
morphisms affect MAOA-promoter function. Alleles
with longer repeats—3a, 4, and 5—are consistentlymore
active in transfected cells than is the shorter, three-repeat
allele. We have not tested allele 2, which is very rare in
the populations that we have studied. Furthermore, the
more actively expressed alleles are found at a signifi-
cantly greater frequency among affected females than
among control females. Curiously, no significant differ-
ences were observed between male patients and male
controls (Deckert et al. 1999), although, given the link-
age of MAOA to the X chromosome, males would be
expected to be more, not less, sensitive to differences in
genotype at this locus, as has been seen in studies of
aggression (Shih and Thompson 1999 [in this issue]).
These findings may indicate that, in panic disorder, the
etiopathogenetic pathways that are important are dif-
ferent in males versus females; this possibility is sup-
ported by other psychopharmacogenetic data. A nearly
concomitant clinical study, which used artificial neural
networks to model the efficacy of treatments for this
condition, appears to confirm the sex difference that we
observe and to suggest that, to control the symptoms of
panic disorder, different therapies be applied in males
versus females. Politi et al. (in press) have shown that
moclobemide, a reversible MAOA inhibitor, works bet-
ter in women with prominent anxiety symptoms than in
men with similar symptoms. This difference seems to be
specific to this class of drugs; no significant difference
in responsiveness to SSRI treatment, which is commonly
used in patients with panic and anxiety disorder, can be
found between sexes. These results, along with our as-
sociation data, may suggest that MAOA inhibitors are
a good choice in the treatment of females with panic
disorder.
The Future of Psychopharmacogenetics
Recent trends justify some measured optimism about
the prospects for psychopharmacogenetics. It now seems
clear that psychiatrists and pharmacologists should not
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regard each other’s fields merely as tools to solve their
own problems but, rather, should note that an interesting
set of questions is developing as a result of interactions
between these disciplines. Both the development of more
sophisticated molecular approaches and the growing in-
terest in regulatory-sequence polymorphisms may finally
make the pharmacogenetic approach useful in the psy-
chiatric clinic.
Genetic analysis of responses to psychoactive drugs
clearly has much to offer, but large and small chal-
lenges remain. The goal of applying well-tailored in-
dividual therapies to relieve or even prevent the onset
of symptoms will require us to make precise psychi-
atric diagnoses and to develop selective drugs. At pre-
sent, establishing a diagnosis still seems to present
intractable problems, and patterns of drug respon-
siveness are of limited help in this regard. Response
to the same drug does not always mean that there are
identical pathogenetic pathways: SSRIs are advanta-
geous in the treatment of both depression and obses-
sive-compulsive disorder, but the effects of the 5-
HTT–promoter polymorphism on SSRI response seem
to be restricted to the former condition (Billet et al.
1997). Conversely, lack of responsiveness to a given
drug does not always mean a misdiagnosis, since re-
fractory patients are an unfortunate reality. Molecular
geneticists will likely concentrate their efforts either
on genes with relatively large effects on pathogenesis
or on those genes whose products represent direct tar-
gets of specific drugs. It is worth recalling, however,
that psychiatric disorders are multifactorial and mul-
tigenic and that genes that are associated with a minor
risk of disease could play a significant role in deter-
mining the response to treatment.
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